Phase 2 N=12 LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Multiple Myeloma
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Neoadjuvant and Adjuvant Checkpoint Blockade
Cutaneous Melanoma · Mucosal Melanoma · Ocular Melanoma
Primary: Arm C: Number of Participants With the Pathologic Response Rate — 0; 0; 34 Participants
Phase 2 N=40 Oxytocin and Social Cognitive Skills Groups
Autism Spectrum Disorder
Primary: Change From Baseline in Social Behavior Impairment (SBI) Composite — 0.12; -0.14; -0.26; -0.16 z-score — p=0.037
Phase 2 N=230 Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
Chronic Hand Eczema
Primary: Cohort 1: Number of Participants With ≥1 Adverse Event (AE) — 1 Participants
Phase 2 N=91 Chemoprevention of Gastric Carcinogenesis
Gastric Cancer · Gastric Intestinal Metaplasia
Primary: The Difference in Cell DNA Damage, Based on Percent Positive Cells, Between Patients Treated With DFMO and Patients Treated With Placebo at 6 Months. — 5.07; 7.32…
Phase 2 N=28 Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
COVID-19
Primary: Percentage of Patients Who Are Alive and Free From Advanced Respiratory Support Measures at Day 28. — 15; 8 Participants
Phase 2 N=376 Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 41.5; 45.3 Percentage of participants
Phase 2 N=47 SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)
COVID-19 · Lung Injury, Acute · Kidney Injury
Primary: Change in COVID Disease Status — 5.09; 5.48; 3.05; 3.00 score on a scale
Phase 2 N=62 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 2; 1; 1 Participants
Phase 2 N=78 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Brain and Central Nervous System Tumors · Intraocular Melanoma · Lung Cancer
Primary: Six-month Overall Survival — 67; 11 Participants
Phase 2 N=13 Treatment for Calcium Phosphate Kidney Stone Disease
Calcium Phosphate Kidney Stones
Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units
Phase 2 N=79 Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer
Postoperative Stage II/III Colon Cancer
Primary: The Cumulative Rates of Participants With NCI-CTCAE Grade 2 or Higher Peripheral Sensory Neuropathy: Up to End of Study Treatment — 11; 11; 18 Participants
Phase 2 N=27 Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
T-cell Lymphomas · Relapsed or Refractory
Primary: Maximum Tolerated Dose of Romidepsin — 8; 8 mg/m^2 romidepsin
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
Phase 2 N=137 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) — 35.8 percentage of participants